Document Detail


The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.
MedLine Citation:
PMID:  1520648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
TIBET is a European multicenter, double-blind parallel group trial with the main objective of investigating whether total ischemic burden has important prognostic implications in patients with stable angina on treatment. A secondary objective is to compare the antianginal and antiischemic effects of atenolol (50 mg bid), nifedipine (20-40 mg bid), and their combination using standardized exercise testing and Holter monitoring techniques. The main primary end points are cardiovascular morbidity and mortality. The secondary end points are time to onset of significant ischemia, angina on exercise stress testing, exercise capacity at onset of angina, 1-mm ST-segment depression and termination of exercise, total duration and number of significant ischemic episodes during 48 hours of Holter monitoring, and their circadian distribution. The target population, the assessments, and the management of the trial are described in detail.
Authors:
-
Related Documents :
3934948 - Comparison of diltiazem and nifedipine for both angina pectoris and systemic hypertension.
10201458 - Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright...
3943938 - Cardiac adaptations to training: relevance to angina pectoris.
2257858 - The cardiovascular effects of oral nifedipine and nicardipine: a double-blind compariso...
9375348 - Human growth hormone response to repeated bouts of aerobic exercise.
25381558 - Diffusion limitations of the lung - comparison of different measurement methods.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  6     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1992 Aug 
Date Detail:
Created Date:  1992-10-09     Completed Date:  1992-10-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  379-86     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angina Pectoris / complications,  drug therapy*,  mortality
Atenolol / therapeutic use*
Coronary Disease / etiology*
Data Interpretation, Statistical
Double-Blind Method
Drug Therapy, Combination
Electrocardiography, Ambulatory
Exercise Test
Female
Humans
Male
Middle Aged
Nifedipine / therapeutic use*
Prognosis
Chemical
Reg. No./Substance:
21829-25-4/Nifedipine; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency...
Next Document:  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term eff...